Browse trials that we are currently enrolling for by condition and associated pharmaceutical company.
Nonalcoholic Steatohepatitis (NASH)
Viking
VK2809 a phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of VK2809 administered for 52 weeks followed by a 4-week off-drug phase in subjects with biopsy proven non-alcoholic steatohepatitis with fibrosis(stage 1-3).
Galactin
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis.
Crohn’s
Eli Lilly(AMAM)
This is a Phase 3, multicenter, randomized, double-Blind, placebo- and active- controlled, treat-through study to evaluate the efficacy and safety of mirikizumab in subjects who have moderately to severely active Crohn’s disease. Participants were divided into three study arms: the experimental group received intravenous (IV) and subcutaneous (SC) injections of mirikizumab; the group in the active comparator group received IV and SC injections of ustekinumab; the subjects in the placebo comparator group received placebo IV and SC injections.
Arena(cultivate)
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease.
Screening Colonoscopy
Guardant
The GuardantLUNAR-2 test is an NGS-based plasma assay which derives a binary qualitative result for a patient’s risk of colorectal cancer. No results from the test will be returned to either the patient or the investigator and therefore no treatment decisions will be based upon the results.
Ulcerative Colitis
Eli Lilly (AMBI)
The purpose of this study is to evaluate if study drug mirikizumab is safe and effective compared to vedolizumab and placebo in participants with moderately to severely active ulcerative colitis (UC).
Suzhou
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC). CBP-307 capsules are administered orally. This study includes stage 1 and stage 2. After screening, subjects will enter the randomized, double-blind, placebo-controlled induction therapy for 12 weeks, i.e., the study stage 1. All subjects who complete 12 weeks of induction therapy (with CBP-307 or placebo) in the study stage 1 and complete all examinations (including colonoscopy) at the week 12 visit can choose to enter the study stage 2 of a total of 40 weeks, including 36 weeks of continuous administration and 4 weeks of safety follow-up after the last dose.
Eosinophilic Esophagitis
Arena 206
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
